ArticlesGlycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
Introduction
Guidelines for the management of hyperglycaemia in type 2 diabetes recommend metformin as first-line pharmacological therapy,1, 2 with sequential intensification and second-line therapy only when glycaemic control (glycated haemoglobin A1c [HbA1c] ≤53 mmol/mol or ≤7·0%) is not achieved. However, with clinical inertia, treatment intensification is often delayed, resulting in loss of glycaemic control3 and exposure to avoidable hyperglycaemia. The UK Prospective Diabetes Study4 established that early treatment to lower glycaemia using metformin was associated with reduction in myocardial infarction, diabetes-related deaths, and all-cause mortality, and a legacy of continued benefit after 10 years. Recent studies5 have highlighted the importance of achieving early glycaemic control within the first 12 months of diagnosis, as this improves long-term glycaemic durability and reduces the risk of associated complications.
One potential strategy to improve the achievement and maintenance of glycaemic control is to introduce combination therapy with two or more agents as early as possible. The rationale for this approach is based on the multiple pathophysiologic mechanisms underlying chronic hyperglycaemia,6 and the complementary mechanisms of action of available glucose-lowering agents.7, 8 In a recent meta-analysis of 15 randomised clinical trials evaluating initial combination therapy with metformin versus metformin monotherapy in patients with untreated type 2 diabetes, Phung and colleagues9 reported that combination therapy with metformin significantly reduced HbA1c, increased attainment of HbA1c below 53 mmol/mol (7·0%), and reduced fasting plasma glucose compared with metformin alone.
Despite these encouraging results, the most recent American Diabetes Association and European Association for the Study of Diabetes consensus statement1 for the treatment of hyperglycaemia in type 2 diabetes noted that although there is some support for early combination therapy because of the greater initial reduction of HbA1c compared with metformin alone, evidence for the superiority of the strategy of early combination therapy over later combination therapy for maintaining glycaemic control is scarce.
The Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of type 2 diabetes (VERIFY) study was therefore designed as a 5-year efficacy and safety study, comparing an early combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor vildagliptin with standard-of-care metformin monotherapy, defined as a traditional stepwise approach with metformin as initial therapy and vildagliptin added at the time of metformin failure. The choice of exploring the combination of a dipeptidyl peptidase-4 inhibitor with metformin is supported by glucose-dependent β-cell stimulation by vildagliptin7 and concomitant insulin sensitisation by metformin,10 as well as the established favourable safety profile of both drugs.7, 11
Section snippets
Study design and participants
The VERIFY study design has been previously reported.12 Briefly, VERIFY was a randomised, double-blind, parallel-group study of newly diagnosed patients with type 2 diabetes conducted in 254 centres across 34 countries. The study consisted of a 2-week screening visit, a 3-week metformin-alone run-in period, and a 5-year treatment period, which was further split into study periods 1, 2, and 3. During the 5-year treatment period, treatment was initially intensified when loss of glycaemia occurred
Results
Trial enrolment began on March 30, 2012, and was completed on April 10, 2014. The last trial visit was on April, 2019. Of the 4524 participants screened, 2001 eligible participants15 were randomly assigned to either the early combination treatment group (n=998) or the initial metformin monotherapy group (n=1003; figure 2). The most common reasons for study exclusion were HbA1c outside the protocol-defined range and metformin intolerance prior to up-titration. A total of 1598 (79·9%) patients
Discussion
The VERIFY study has shown that early combination treatment with metformin and vildagliptin improves glycaemic durability in patients with type 2 diabetes compared with standard-of-care initial metformin monotherapy followed by sequential combination with vildagliptin. Early combination treatment significantly reduced the probability of initial treatment failure, the time to second treatment failure, and the time to treatment failure compared with monotherapy throughout the 5-year study
Data sharing
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymised to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The criteria and process for trial data availability are described online.
References (31)
- et al.
Reducing insulin resistance with metformin: the evidence today
Diabetes Metab
(2003) Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin–diabetes control and potential adverse events
Best Pract Res Clin Endocrinol Metab
(2009)- et al.
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetes Care
(2018) - et al.
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm—2019 executive summary
Endocr Pract
(2019) - et al.
Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people
Diabetes Care
(2013) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
Lancet
(1998)- et al.
The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study)
Diabetes Care
(2019) - et al.
Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes
Diabetes Care
(2013) - et al.
The islet enhancer vildagliptin: mechanisms of improved glucose metabolism
Int J Clin Pract Suppl
(2008) - et al.
Oral antihyperglycemic therapy for type 2 diabetes mellitus
CMAJ
(2005)
Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis
Diabetes Obes Metab
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
Diabetes Obes Metab
Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial
Diabet Med
ICH harmonised tripartite guideline: guideline for good clinical practice
A pre-specified statistical analysis plan for the VERIFY study: vildagliptin efficacy in combination with metformin for early treatment of T2DM
Diabetes Obes Metab
Cited by (210)
International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes
2024, Diabetes Research and Clinical PracticeComparison of beta-cell function between Hong Kong Chinese with young-onset type 2 diabetes and late-onset type 2 diabetes
2023, Diabetes Research and Clinical PracticeNAD metabolism modulates inflammation and mitochondria function in diabetic kidney disease
2023, Journal of Biological ChemistryMultifunctional nanoparticle-mediated combining therapy for human diseases
2024, Signal Transduction and Targeted TherapyExpert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective
2024, Clinical Medicine Insights: Endocrinology and Diabetes